All Stories

  1. Exploring the dichotomy of the mesenchymal stem cell secretome: Implications for tumor modulation via cell-signaling pathways

    Article • International Immunopharmacology, December 2024, Elsevier

    Dr Raheleh Roudi

  2. Patient-Derived Organoids: A Game-Changer in Personalized Cancer Medicine

    Article • Stem Cell Reviews and Reports, October 2024, Springer Science + Business Media

    Dr Raheleh Roudi

  3. Association Study between rs10486567, rs13149290, rs1545985 and rs6983267 with Incidence of Prostate Adenocarcinoma Among Iranians

    Article • Current Pharmacogenomics and Personalized Medicine, July 2024, Bentham Science Publishers

    Dr Raheleh Roudi

  4. Reproducibility and repeatability of quantitative T2 and T2* mapping of osteosarcomas in a mouse model

    Article • European Radiology Experimental, June 2024, Springer Science + Business Media

    Dr Raheleh Roudi

  5. Regulation of Cellular-Signaling Pathways by Mammalian Proteins Containing Bacterial EPIYA or EPIYA-Like Motifs Predicted to be Phosphorylated

    Article • DNA and Cell Biology, December 2023, Mary Ann Liebert Inc

    Dr Raheleh Roudi

  6. Integrating DNA methylation and gene expression data in a single gene network using the iNETgrate package

    Article • Scientific Reports, December 2023, Springer Science + Business Media

    Dr Raheleh Roudi

  7. Novel Clinically Translatable Iron Oxide Nanoparticle for Monitoring Anti-CD47 Cancer Immunotherapy

    Article • Investigative Radiology, October 2023, Wolters Kluwer Health

    Dr Raheleh Roudi

  8. Investigating the Association of rs4962416 and rs6465657 with Prostate Adenocarcinoma in the Iranian Population

    Article • Current Pharmacogenomics and Personalized Medicine, August 2023, Bentham Science Publishers

    Dr Raheleh Roudi, Seyed Abdolhamid Angaji

  9. Measurement of Tumor T2* Relaxation Times after Iron Oxide Nanoparticle Administration

    Article • Journal of Visualized Experiments, May 2023, MyJove Corporation

    Dr Raheleh Roudi

  10. Co-Clinical Imaging Metadata Information (CIMI) for Cancer Research to Promote Open Science, Standardization, and Reproducibility in Preclinical Imaging

    Article • Tomography, May 2023, MDPI AG

    Dr Raheleh Roudi

  11. Association study between rs1571801 and rs16260 with prostate adenocarcinoma predisposition in Iranian population

    Article • Egyptian Journal of Medical Human Genetics, May 2023, Springer Science + Business Media

    Dr Raheleh Roudi

  12. Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials

    Article • Tomography, March 2023, MDPI AG

    Dr Raheleh Roudi

  13. MegaPro, a clinically translatable nanoparticle for in vivo tracking of stem cell implants in pig cartilage defects

    Article • Theranostics, January 2023, Ivyspring International Publisher

    Dr Raheleh Roudi

  14. The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment

    Article • Cancers, October 2022, MDPI AG

    Dr Raheleh Roudi

  15. RNA‐sequencing for transcriptional profiling of whole blood in early stage and metastatic pancreatic cancer patients

    Article • Cell Biology International, October 2022, Wiley

    Dr Raheleh Roudi

  16. Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer

    Article • Cancers, June 2022, MDPI AG

    Dr Raheleh Roudi

  17. Identification of hub genes, modules and biological pathways associated with lung adenocarcinoma: A system biology approach

    Article • Gene Reports, June 2022, Elsevier

    Dr Raheleh Roudi

  18. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects

    Article • International Immunopharmacology, December 2021, Elsevier

    Dr Raheleh Roudi

  19. p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis

    Article • Molecules, October 2021, MDPI AG

    Dr Raheleh Roudi

  20. Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis

    Article • Immunotherapy, March 2021, Future Medicine

    Dr Raheleh Roudi

  21. CTLA-4 in Regulatory T Cells for Cancer Immunotherapy

    Article • Cancers, March 2021, MDPI AG

    Dr Raheleh Roudi

  22. CTLA-4 in Regulatory T Cells for Cancer Immunotherapy

    Article • February 2021, MDPI AG

    Dr Raheleh Roudi

  23. Identification of potential common molecular factors of pancreatic cancer and diabetes mellitus using microarray data analysis combined with bioinformatics techniques and experimental validation

    Article • Biomedical and Biotechnology Research Journal (BBRJ), January 2021, Medknow

    Dr Raheleh Roudi

  24. Expression patterns and clinical significance of the potential cancer stem cell markers OCT4 and NANOG in colorectal cancer patients

    Article • Molecular & Cellular Oncology, July 2020, Taylor & Francis

    Dr Raheleh Roudi

  25. Potential theranostics of circulating tumor cells and tumor-derived exosomes application in colorectal cancer

    Article • Cancer Cell International, July 2020, Springer Science + Business Media

    Dr Raheleh Roudi

  26. Immunotherapy‑based combinations versus standard first‑line and hypothyroidism risk

    Article • Revista de Oncología, April 2020, Springer Science + Business Media

    Dr Raheleh Roudi

  27. Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics

    Article • Frontiers in Oncology, December 2019, Frontiers

    Dr Raheleh Roudi

  28. The relationship between KLK3 rs17632542 and PRNCR1 rs16901979 polymorphisms with susceptibility to prostate cancer

    Article • Meta Gene, September 2019, Elsevier

    Dr Raheleh Roudi

  29. High GD2 expression defines breast cancer cells with enhanced invasiveness

    Article • Experimental and Molecular Pathology, August 2019, Elsevier

    Professor of Neurogenetics Isa Abdi Rad, Dr Raheleh Roudi

  30. Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights

    Article • Journal of Oncology, July 2019, Hindawi Publishing Corporation

    Dr Raheleh Roudi

  31. Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis

    Article • Future Oncology, July 2019, Future Medicine

    Dr Raheleh Roudi

  32. Dendritic cell/cytokine‐induced killer cell‐based immunotherapy in lung cancer: What we know and future landscape

    Article • Journal of Cellular Physiology, June 2019, Wiley

    Dr Raheleh Roudi

  33. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis

    Article • BMC Cancer, June 2019, Springer Science + Business Media

    Dr Raheleh Roudi

  34. CD44 epithelial isoform inversely associates with invasive characteristics of colorectal cancer

    Article • Biomarkers in Medicine, April 2019, Future Medicine

    Dr Raheleh Roudi

  35. Co‐expression of TLR ‐9 and MMP ‐13 is associated with the degree of tumour differentiation in prostate cancer

    Article • International Journal of Experimental Pathology, April 2019, Wiley

    Dr Raheleh Roudi

  36. Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy

    Article • Cancer Biotherapy & Radiopharmaceuticals, April 2019, Mary Ann Liebert Inc

    Dr Raheleh Roudi

  37. Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma

    Article • Frontiers in Oncology, February 2019, Frontiers

    Dr Raheleh Roudi

  38. Induction of miR-31 causes increased sensitivity to 5-FU and decreased migration and cell invasion in gastric adenocarcinoma

    Article • Bratislava Medical Journal, January 2019, AEPress, s.r.o.

    Dr Raheleh Roudi

  39. Association of homeobox B13 (HOXB13) gene variants with prostate cancer risk in an Iranian population

    Article • Medical Journal of the Islamic Republic of Iran, September 2018, Academic World Research

    Dr Raheleh Roudi

  40. Do statins improve outcomes for patients with non-small cell lung cancer? A systematic review and meta-analysis protocol

    Article • BMJ Open, September 2018, BMJ

    Dr Raheleh Roudi

  41. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients

    Article • PLoS ONE, July 2018, PLOS

    Dr Raheleh Roudi

  42. Association of Homeobox B13 (HOXB13) Gene Variants with Prostate Cancer Risk in Iranian Population

    Article • July 2018, MDPI AG

    Dr Raheleh Roudi

  43. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol

    Article • Cochrane Database of Systematic Reviews, April 2018, Wiley

    Dr Raheleh Roudi

  44. Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention

    Article • Journal of Human Genetics, April 2018, Springer Science + Business Media

    Dr Raheleh Roudi

  45. Resisting resistance to cancer immunotherapy

    Article • Thoracic Cancer, March 2018, Wiley

    Dr Raheleh Roudi

  46. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent

    Article • Cochrane Database of Systematic Reviews, December 2017, Wiley

    Dr Raheleh Roudi

  47. Lgr5High/DCLK1High phenotype is more common in early stage and intestinal subtypes of gastric carcinomas

    Article • Cancer Biomarkers, December 2017, IOS Press

    Dr Raheleh Roudi

  48. DNA Microarray

    Article • The Open Microbiology Journal, November 2017, Bentham Science Publishers

    Assistant Professor Payam BEHZADI, Dr Raheleh Roudi

  49. Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer

    Article • Medicine, November 2017, Wolters Kluwer Health

    Dr Raheleh Roudi

  50. Antimicrobial Peptides As Biologic and Immunotherapeutic Agents against Cancer: A Comprehensive Overview

    Article • Frontiers in Immunology, October 2017, Frontiers

    Dr Raheleh Roudi

  51. Increased Expression of ALDH1A1 in Prostate Cancer is Correlated With Tumor Aggressiveness

    Article • Applied Immunohistochemistry & Molecular Morphology, September 2017, Wolters Kluwer Health

    Dr Raheleh Roudi

  52. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells

    Article • Experimental Biology and Medicine, August 2017, SAGE Publications

    Dr Raheleh Roudi

  53. Cancer stem cell research in Iran: potentials and challenges

    Article • Future Oncology, August 2017, Future Medicine

    Dr Raheleh Roudi

  54. Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma

    Article • Pathology - Research and Practice, June 2017, Elsevier

    Dr Raheleh Roudi

  55. Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?

    Article • Clinical and Experimental Medicine, April 2017, Springer Science + Business Media

    Dr Raheleh Roudi

  56. Lung cancer and β-glucans: review of potential therapeutic applications

    Article • Investigational New Drugs, March 2017, Springer Science + Business Media

    Dr Raheleh Roudi

  57. Expression of Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas

    Article • Applied Immunohistochemistry & Molecular Morphology, March 2017, Wolters Kluwer Health

    Dr Raheleh Roudi

  58. Differential role of Wnt signaling and base excision repair pathways in gastric adenocarcinoma aggressiveness

    Article • Clinical and Experimental Medicine, December 2016, Springer Science + Business Media

    Dr Raheleh Roudi

  59. Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma

    Article • Tumor Biology, April 2016, Springer Science + Business Media

    Dr Raheleh Roudi

  60. Accuracy of c-KIT in lung cancer prognosis; a systematic review protocol" instead of c-KIT Expression in Lung Cancer Prognostic Evaluation - a Systematic Review Protocol

    Article • Asian Pacific Journal of Cancer Prevention, March 2016, Asian Pacific Organization for Cancer Prevention

    Dr Raheleh Roudi

  61. Comparative Expression Analysis of Putative Cancer Stem Cell Markers CD44 and ALDH1A1 in Various Skin Cancer Subtypes

    Article • The International Journal of Biological Markers, January 2016, SAGE Publications

    Dr Raheleh Roudi

  62. Diagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: a systematic review protocol

    Article • BMJ Open, January 2016, BMJ

    Dr Abbas Ali Keshtkar, Dr Raheleh Roudi

  63. Evaluation of anaplastic lymphoma kinase expression in nonsmall cell lung cancer;a tissue microarray analysis

    Article • Journal of Cancer Research and Therapeutics, January 2016, Medknow

    Dr Raheleh Roudi

  64. Erratum: Evaluation of anaplastic lymphoma kinase expression in nonsmall cell lung cancer; a tissue microarray analysis

    Article • Journal of Cancer Research and Therapeutics, January 2016, Medknow

    Dr Raheleh Roudi

  65. Comparative gene-expression profiling of CD133+ and CD133- D10 melanoma cells

    Article • Future Oncology, September 2015, Future Medicine

    Dr Raheleh Roudi

  66. Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes

    Article • Cancer Investigation, June 2015, Taylor & Francis

    Dr Raheleh Roudi

  67. Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer

    Article • Cancer Biomarkers, October 2014, IOS Press

    Dr Raheleh Roudi

  68. CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549

    Article • Cellular & Molecular Biology Letters, January 2014, De Gruyter

    Dr Raheleh Roudi